Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation
Article first published online: 1 DEC 2011
Published 2011. This article is a U.S. Government work and is in the public domain in the USA.
Clinical & Experimental Immunology
Volume 167, Issue 1, pages 40–46, January 2012
How to Cite
Brooks-Worrell, B. and Palmer, J. P. (2012), Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clinical & Experimental Immunology, 167: 40–46. doi: 10.1111/j.1365-2249.2011.04501.x
- Issue published online: 1 DEC 2011
- Article first published online: 1 DEC 2011
- Accepted manuscript online: 12 OCT 2011 08:14AM EST
- Accepted for publication 29 September 2011
- inflammation/inflammatory mediators including eicosanoids;
- T cells
OTHER THEMES PUBLISHED IN THIS IMMUNOLOGY IN THE CLINIC REVIEW SERIES
Allergy, Host Responses, Cancer, Autoinflammatory Diseases, Type 1 diabetes and viruses.
Historically, the development of type 2 diabetes has been considered not to have an autoimmune component, in contrast to the autoimmune pathogenesis of type 1 diabetes. In this review we will discuss the accumulating data supporting the concept that islet autoreactivity and inflammation is present in type 2 diabetes pathogenesis, and the islet autoimmunity appears to be one of the factors associated with the progressive nature of the type 2 diabetes disease process.